Conference Coverage
Latest News
Jul 11, 2026 | News
Social Media Mythbusters: PDRN Serums
The Gut-Skin Axis: New Evidence Links Microbiota to Skin Disease via Inflammatory Cytokines
Jul 10, 2026
Tralokinumab Meets Pharmacokinetic Goal in Pediatric AD Phase 2 Trial
Jul 10, 2026
Psychiatric Risk in CSU May Be More Limited Than Previously Thought
Jul 10, 2026
Breakout Bulletin: July 6-July 10
Jul 10, 2026
Videos
Advertisement
Shorts
0:47
Why Patient Stratification Matters in Clinical Trials
2 days ago
by
Bradley Burnam
0:56
The Importance of Early PsA Treatment for Joint Health
3 days ago
by
Philip J. Mease, MD
0:31
Why Your Acne Treatments May Not Be Working
4 days ago
by
Kord Honda, MD
0:24
Why patients are moving away from injectable psoriasis treatments
5 days ago
by
Linda Stein Gold, MD
1:10
A Win for Patients and Providers: Roflumilast’s Expanded PsO Indication
10 days ago
by
Christopher G. Bunick, MD, PhD
1:00
Roflumilast Cream Approved for Children as Young as 2 With Plaque Psoriasis
11 days ago
by
Jennifer Soung, MD
0:28
Rethinking First-Line Treatment for Atopic Dermatitis
15 days ago
by
David Cotter, MD, PhD
2:18
What AbbVie’s Acquisition of Apogee Means for AD Treatment
15 days ago
by
Christopher G. Bunick, MD, PhD
0:42
When Patients Fear Their AD Medication
16 days ago
by
Mona Shahriari, MD, FAAD
0:35
The Myths Surrounding Food Allergies and Atopic Dermatitis
17 days ago
by
Jennifer Soung, MD
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.
Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.
New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.
Career decisions in dermatology are too often driven by emotion rather than data, according to a new practice management column examining common pitfalls in contract evaluation and compensation negotiations.
Innovations in packaging, formulation design, and alternative preservation strategies may reduce preservative concentrations, but they are unlikely to eliminate the need for preservatives entirely.
Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.
Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
Continuing Medical Education
All News
Advertisement
Advertisement
Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!
The Cutaneous Connection: Representation, Education, and Revolutionizing Sunscreen for Skin of Color
In this episode, Black Girl Sunscreen CEO Shontay Lundy reveals why skin of color needs photoprotection, better formulas, and stronger clinician-industry collaboration.
Forte Biosciences' FB102 shows significant facial repigmentation in a phase 1b vitiligo trial, with gains continuing 12 weeks post-treatment and mild adverse effects.
Learn the 10 weekly dashboard metrics Kathleen Moe, MD, tracks to spot issues early, boost access, cash flow, and patient experience in her practice.
Lynk Pharmaceuticals has dosed the first patient in a phase 2 trial evaluating investigational topical pan-JAK inhibitor LNK01004 for vitiligo.
A JAMA Dermatology study suggests higher cumulative isotretinoin doses, not higher daily doses, may help reduce acne relapse.
FDA clears SkinStylus microneedling for under-eye wrinkles in all skin types, expanding uses for acne and abdominal scars amid booming aesthetics demand.
The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.
This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.
A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.
Advertisement
A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.
Teva will advance TEV-'408 into phase 2b after encouraging phase 1b vitiligo data showed repigmentation, favorable safety, and quarterly dosing potential.
New case-control data link smoking to higher nail psoriasis severity, urging screening and cessation to ease nail symptoms and boost quality of life.
Turn Therapeutics finalized its stage 2 trial design after interim data showed clinically meaningful GX-03 efficacy in patients with baseline EASI scores as low as 1.1.
At a recent Dermatology Times Evolving Paradigms event, Nikhil Khushalani, MD, led dermatologists, Mohs surgeons, and oncologists in comparing systemic immunotherapy selection, referral practices, and adverse event management in advanced cutaneous squamous cell carcinoma.
Advertisement
Advertisement
Trending on Dermatology Times
1
Tralokinumab Meets Pharmacokinetic Goal in Pediatric AD Phase 2 Trial
2
The Gut-Skin Axis: New Evidence Links Microbiota to Skin Disease via Inflammatory Cytokines
3
First Patient Dosed in Phase 2 Trial of Topical Pan-JAK Inhibitor LNK01004 for Vitiligo
4
GX-03 Demonstrates Encouraging Safety as Development Continues
5